Cleveland Clinic Joins U.S. Clinical Trial of VERTICA - a Non-Invasive Erectile Dysfunction Treatment

Cleveland Clinic Joins U.S. Clinical Trial of VERTICA - a Non-Invasive Erectile Dysfunction Treatment Already Used by Over 7,000 Men Worldwide

LONDON, UNITED KINGDOM, April 4, 2025 /EINPresswire.com/ -- OHH-MED Medical Ltd., a global leader in innovative treatments for male urology, today announced that Cleveland Clinic has joined the U.S. clinical trial of VERTICA, a non-invasive, at-home medical device for erectile dysfunction (ED). The VERTICA RF device is already in use by more than 7,000 men globally and is now undergoing evaluation in a pivotal FDA-approved U.S. study.

The trial, titled “Safety and Efficacy of the VERTICA RF Device for the Treatment of ED,” is being conducted at several top-tier institutions. At Cleveland Clinic, recruitment is now underway under the leadership of Dr. Petar Bajic, a specialist in male sexual health.

“Adding Cleveland Clinic to the trial brings world-class expertise and further momentum to this important study,” said Daniel Lischinsky, CEO of OHH-MED Medical Ltd. “VERTICA has already helped thousands of men outside the U.S., and this study moves us closer to making it available to millions more seeking a safe, effective, and drug-free solution for ED.”

The randomized, sham-controlled trial includes 98 men, who will receive either the active VERTICA treatment or a placebo. The protocol includes an initial in-clinic session, followed by six months of at-home use, with monthly follow-ups to track safety and efficacy.

U.S. Clinical Trial Sites and Principal Investigators:
• Cleveland Clinic, Cleveland, OH – Dr. Petar Bajic
• Baylor College of Medicine, Houston, TX – Dr. Mohit Khera
• Optimal Health Miami, Aventura, FL – Dr. Marc Gittelman
• San Diego Sexual Medicine, San Diego, CA – Dr. Irwin Goldstein
• University of California, Irvine, Newport Beach, CA – Dr. Faysal Yafi

The VERTICA RF device delivers targeted high-frequency energy to address the root causes of erectile dysfunction, rather than simply relieving symptoms. Unlike oral medications or injections, it is completely non-invasive and designed for convenient use at home.

For more details on the study, including eligibility and site contact information, visit the NIH ClinicalTrials.gov listing: https://clinicaltrials.gov/study/NCT06167733
For participation inquiries, individuals can contact trial sites directly or email the Contract Research Organization (CRO) at tali@asteinrac.com.

Caroline McIntyre
Ohh-Med Medical UK Ltd
+44 7747 566719
email us here